According to Pfizer, "Hundreds of millions of doses of the Pfizer-BioNTech COVID-19 vaccine have been administered globally, and the benefit-risk profile of the vaccine remains positive for all ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

The court determined that Pfizer (NYSE: PFE) and BioNTech’s (NASDAQ: BNTX) Comirnaty vaccine had infringed on this patent, making Moderna eligible for damages for sales after March 2022. In the same ...

Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...

Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 ...

On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and ...

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal. | After several PD ...

The Hong Kong-listed firm is advancing its pipeline using an mRNA system it says can compete with the industry’s best.

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

BioNTech ADR BNTX saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 73. Please ...

Big Pharmas like Eli Lilly, Sanofi and Novartis headed back to the dealmakers table multiple times, with 32 total deals ...

IMM2510, a differentiated PD-L1xVEGF bispecific antibody with upcoming data in H2 2025. Click to read why TIL is a Hold.